Cost‐effectiveness of first‐line systemic therapies for unresectable hepatocellular carcinoma
At a willingness-to-pay threshold of $150 000/QALY, durvalumab is likely the most cost-effective first-line systemic therapy for uHCC compared to sorafenib. Although atezolizumab plus bevacizumab yielded the highest QALYs, their ICERs exceeded the commonly accepted cost-effectiveness threshold ($150 000$ per QALY gained). These findings can inform clinical decision-making, resource allocation and future research priorities in managing uHCC.
Authors
- Yuling Gan
- Dennis Xuan
- Shimeng Liu (ORCID: https://orcid.org/0009-0007-6878-6272)
- Yan Wei (ORCID: https://orcid.org/0000-0001-9079-2379)
- Lian Dai (ORCID: https://orcid.org/0000-0002-4404-7893)
- Dunming Xiao
Institutions
- Tulane University (US)
- Fudan University (CN)
- National Health and Family Planning Commission (CN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1111/bcp.16367
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China